After much anticipation and concern, the BIOSECURE Act—which would prevent U.S. companies from working with certain Chinese biotech service providers—has passed a key threshold. Late Monday, the U.S. House of Representatives voted 306-81 in favor of the bill, which was introduced in January and seeks to halt federal contracts with five named Chinese life-sci companies—WuXi…